logo

Clearside Biomedical, Inc. (CLSD)



Trade CLSD now with
  Date
  Headline
7/11/2018 4:32:14 PM Clearside Biomedical Appoints Carol Hoang As VP, Medical Affairs
5/31/2018 7:42:44 AM Clearside Reports Positive Results From Phase 2 Trial Of CLS-TA Used With Eylea In Patients With Diabetic Macular Edema
5/11/2018 11:20:00 AM Wedbush Is Cutting Clearside Biomedical, Inc. (CLSD) FY19 Estimate To -2.72 From -2.63
5/11/2018 11:19:45 AM Wedbush Is Lowering Clearside Biomedical, Inc. (CLSD) FY18 Estimate To -2.27 From -2.10
5/11/2018 11:19:30 AM Wedbush Is Cutting Clearside Biomedical, Inc. (CLSD) Q4 18 Estimate To -0.61 From -0.59
5/11/2018 11:19:16 AM Wedbush Is Lowering Clearside Biomedical, Inc. (CLSD) Q3 18 Estimate To -0.53 From -0.51
5/11/2018 11:19:03 AM Wedbush Is Lowering Clearside Biomedical, Inc. (CLSD) Q2 18 Estimate To -0.52 From -0.50
5/11/2018 11:18:24 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $29 Price Target
5/9/2018 7:18:04 AM Clearside Biomedical Q1 Net Loss $16.6 Mln Or $0.62/shr Vs Loss $10.4 Mln Or $0.41/Shr Last Year
3/20/2018 6:44:15 AM Wedbush Reiterates Clearside Biomedical, Inc. (CLSD) At Outperform With $29 Price Target
3/20/2018 6:43:01 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) FY18 Estimate To -2.10 From -2.37
3/20/2018 6:42:33 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q4 17 Estimate To -0.59 From -0.67
3/20/2018 6:42:00 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q3 18 Estimate To -0.51 From -0.57
3/20/2018 6:41:12 AM Wedbush Is Raising Clearside Biomedical, Inc. (CLSD) Q2 18 Estimate To -0.50 From -0.56
3/20/2018 6:40:53 AM Wedbush Is Increasing Clearside Biomedical, Inc. (CLSD) Q1 18 Estimate To -0.50 From -0.56
3/14/2018 7:11:36 AM Clearside Biomedical Q4 Net Loss $16.5 Mln Or $0.65/Shr Vs $9.7 Mln Or $0.45/Shr Last Year